Kepos Capital LP Acquires Shares of 230,022 NKGen Biotech, Inc. (NYSE:NKGN)

Kepos Capital LP acquired a new stake in shares of NKGen Biotech, Inc. (NYSE:NKGN) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 230,022 shares of the company’s stock, valued at approximately $151,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Sequoia Financial Advisors LLC increased its holdings in shares of NKGen Biotech by 126.1% during the 4th quarter. Sequoia Financial Advisors LLC now owns 156,000 shares of the company’s stock valued at $102,000 after purchasing an additional 87,000 shares in the last quarter. Magnetar Financial LLC purchased a new stake in NKGen Biotech in the 4th quarter worth $175,000. Finally, Polar Asset Management Partners Inc. increased its holdings in NKGen Biotech by 9.4% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,181,872 shares of the company’s stock worth $447,000 after acquiring an additional 101,872 shares in the last quarter. 76.17% of the stock is currently owned by institutional investors and hedge funds.

NKGen Biotech Stock Down 17.0 %

NKGen Biotech stock opened at $0.16 on Friday. NKGen Biotech, Inc. has a 52-week low of $0.10 and a 52-week high of $2.57. The firm has a market capitalization of $7.19 million, a price-to-earnings ratio of -0.03 and a beta of 0.45. The company has a fifty day simple moving average of $0.43 and a 200-day simple moving average of $0.46.

NKGen Biotech Profile

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.